SLC5A2 and diabetes mellitus: Specifically, recently published positive RCT’s of novel drug classes (SGLT2 inhibitors, GLP-1- receptor agonists) [33–35], not frequently used in DIACORE’s baseline visit, will likely change the pattern of drug use in patients with diabetes.